Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3145
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
There is a parallel epidemic of atrial fibrillation (AF) and hypertension (HTN) occurring globally. Both AF and HTN are no longer confined to the older population. The pathophysiology of AF related to HTN is complex with many inter-related factors. Hypertension causes hypertrophy of the ventricular musculature, dilatation of atria, elevated intracardiac pressures, atrial and ventricular mechanical dysfunction, abnormal expression of ion channels, dysregulation of the renin-angiotensin-aldosterone system, and the autonomic function. The pathophysiological alterations and structural changes that occur in the atria, including architectural subcellular abnormalities fibrosis, are considered to cause atrial cardiomyopathy (atriopathy) predisposing to AF. In this review, we discuss some relevant and combined basic and translational science data related to HTN leading to atriopathy and AF and possible clinical applications in the treatment and prevention of AF in patients with HTN.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jce.16632 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!